Related Experiment Video
Updated: Feb 16, 2026

A Lab-On-A-Chip Platform for Stimulating Osteocyte Mechanotransduction and Analyzing Functional Outcomes of Bone Remodeling
Published on: May 21, 2020
Genotyping of KRAS Mutational Status by the In-Check Lab-on-Chip Platform
Maria Guarnaccia1, Rosario Iemmolo2, Floriana San Biagio3
1Institute of Neurological Sciences, Italian National Research Council, Via Paolo Gaifami 18, 95126 Catania, Italy. maria.guarnaccia@cnr.it.
Abstract:
The KRAS oncogene is involved in the pathogenesis of several types of cancer, particularly colorectal cancer (CRC). The most frequent mutations in this gene are associated with poor survival, increased tumor aggressiveness and resistance to therapy with anti-epidermal growth factor receptor (EGFR) antibodies. For this reason, KRAS mutation testing has become increasingly common in clinical practice for personalized cancer treatments of CRC patients. Detection methods for KRAS mutations are currently expensive, laborious, time-consuming and often lack of diagnostic sensitivity and specificity. In this study, we describe the development of a Lab-on-Chip assay for genotyping of KRAS mutational status. This assay, based on the In-Check platform, integrates microfluidic handling, a multiplex polymerase chain reaction (PCR) and a low-density microarray. This integrated sample-to-result system enables the detection of KRAS point mutations, including those occurring in codons 12 and 13 of exon 2, 59 and 61 of exon 3, 117 and 146 of exon 4. Thanks to its miniaturization, automation, rapid analysis, minimal risk of sample contamination, increased accuracy and reproducibility of results, this Lab-on-Chip platform may offer immediate opportunities to simplify KRAS genotyping into clinical routine.
Insights
A new Lab-on-Chip assay simplifies KRAS genotyping for colorectal cancer (CRC) patients. This rapid, accurate method aids personalized treatment by detecting key KRAS mutations, improving clinical routine diagnostics.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- KRAS mutations drive colorectal cancer (CRC) pathogenesis, correlating with poor prognosis and resistance to anti-EGFR therapies.
- KRAS mutation testing is crucial for personalized CRC treatment, but current methods are costly, slow, and lack sensitivity.
- There is a need for efficient, accurate KRAS mutation detection in clinical settings.
Purpose of the Study:
- To develop and validate a novel Lab-on-Chip assay for KRAS genotyping in colorectal cancer.
- To create an integrated sample-to-result system for rapid and accurate detection of KRAS mutations.
- To assess the potential of this platform for routine clinical use.
Main Methods:
- Development of a Lab-on-Chip assay utilizing the In-Check platform.
- Integration of microfluidic handling, multiplex polymerase chain reaction (PCR), and low-density microarray.
- Detection of KRAS point mutations across multiple codons (12, 13, 59, 61, 117, 146) in exons 2, 3, and 4.
Main Results:
- The Lab-on-Chip assay successfully integrated microfluidics, multiplex PCR, and microarray for KRAS genotyping.
- The system demonstrated the ability to detect KRAS mutations in codons 12, 13, 59, 61, 117, and 146.
- The assay offers miniaturization, automation, rapid analysis, and high accuracy and reproducibility.
Conclusions:
- The developed Lab-on-Chip assay provides a simplified and efficient method for KRAS genotyping.
- This platform has the potential to significantly improve the clinical routine for personalized CRC treatment.
- The assay's advantages include speed, accuracy, and reproducibility, addressing limitations of current detection methods.
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Viral Mutations
Protein Folding Quality Check in the RER
Mutation, Gene Flow, and Genetic Drift
Flame Photometry: Lab

